2019
Pediatric Quality of Life Inventory (PedsQL) in Fragile X Syndrome
Fitzpatrick S, Schmitt L, Adams R, Pedapati E, Wink L, Shaffer R, Sage J, Weber J, Dominick K, Erickson C. Pediatric Quality of Life Inventory (PedsQL) in Fragile X Syndrome. Journal Of Autism And Developmental Disorders 2019, 50: 1056-1063. PMID: 31728808, PMCID: PMC7232688, DOI: 10.1007/s10803-019-04292-7.Peer-Reviewed Original Research
2017
Challenges in Conducting Clinical Trials for Pharmacotherapies in Fragile X Syndrome: Lessons Learned
Harkins C, Dominick K, Wink L, Pedapati E, Shaffer R, Fitzpatrick S, Davenport M, Sweeney J, Erickson C. Challenges in Conducting Clinical Trials for Pharmacotherapies in Fragile X Syndrome: Lessons Learned. Pharmaceutical Medicine 2017, 31: 235-244. DOI: 10.1007/s40290-017-0199-1.Peer-Reviewed Original ResearchAutism spectrum disorderFragile X syndromeBehavioral outcome measuresClinician-reported instrumentsUse of parentsBehavioral measuresEye gazeSpectrum disorderNeuroscientific advancesReport instrumentX syndromeTreatment developmentCommon single gene causeBrain functionRater biasBehavioral heterogeneityIntellectual disabilityPharmacotherapy trialsOutcome measuresPotential explanationTreatment-associated changesQuantitative measuresMeasuresDisordersFuture success
2016
A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome
Greiss Hess L, Fitzpatrick S, Nguyen D, Chen Y, Gaul K, Schneider A, Lemons Chitwood K, Eldeeb M, Polussa J, Hessl D, Rivera S, Hagerman R. A Randomized, Double-Blind, Placebo-Controlled Trial of Low-Dose Sertraline in Young Children With Fragile X Syndrome. Journal Of Developmental And Behavioral Pediatrics 2016, 37: 619-628. PMID: 27560971, PMCID: PMC5039060, DOI: 10.1097/dbp.0000000000000334.Peer-Reviewed Original ResearchConceptsLow-dose sertralineEL developmentFragile X syndromeYoung childrenSensory Processing Measure–PreschoolVisual perceptual abilitiesAutism spectrum disorderSocial participationLong-term side effectsPerceptual abilitiesMullen ScalesLanguage developmentSpectrum disorderX syndromeAge equivalentsSide effectsSertraline armClinical Global Impression Scale-ImprovementMSELEarly childhoodSelective serotonin reuptake inhibitorsGlobal clinical improvementChildrenPlacebo-controlled trialSerious adverse eventsPharmacotherapy for Fragile X Syndrome: Progress to Date
Davenport M, Schaefer T, Friedmann K, Fitzpatrick S, Erickson C. Pharmacotherapy for Fragile X Syndrome: Progress to Date. Drugs 2016, 76: 431-445. PMID: 26858239, DOI: 10.1007/s40265-016-0542-y.Peer-Reviewed Original ResearchConceptsFragile X Mental Retardation ProteinGamma-aminobutyric acid (GABA) neurotransmissionMore objective outcome measuresPlacebo-controlled trialFragile X syndromeClinical study designObjective outcome measuresSymptomatic treatmentLoss of FMRPFuture trialsExcessive glutamateOutcome measuresSelective antagonistClinical investigationSingle treatmentStudy designSymptomatic perspectiveGenetic causeX syndromeMental retardation proteinTrialsDrug developmentTreatmentSyndromeDrugs